04 / Section

About

Cell-Ag is an independent publication covering cell agriculture: the research, the scale-up, the regulation and the money. Cultivated food products are one part of that beat, not the whole of it.

Cell-Ag is an independent publication covering cell agriculture: the research, the scale-up, the regulation and the money. Editorial responsibility rests with the Chief Editor, and nothing is published without his review and approval.

What we cover

Three beats, deliberately narrow: cultivated meat and seafood, precision fermentation, and the cell-agriculture supply chain that serves both: media, scaffolds, tanks and the regulators who sign off on the result. We do not cover plant-based analogues except where they share a factory or a shelf.

Contact

Tips, corrections and complaints all go to the same place, the desk. Corrections run in the next editor's column rather than quietly in the archive. Our standards are set out in the editorial policy, and our funding is itemised under disclosure.

The desk

Dr. Benjamin Zamanian

Chief Editor

Cell-Ag is honoured to have Dr. Benjamin Zamanian as its Chief Editor.

Dr. Zamanian is a scientist, inventor and biotechnology entrepreneur with more than fifteen years in biomaterials, tissue engineering and cellular agriculture. His research began within the Harvard-MIT Health Sciences and Technology ecosystem at Brigham and Women's Hospital, with further executive study at Harvard Business School, MIT and MIT Sloan, Yale School of Management and Stanford University.

His work spans hydrogel and microgel engineering, edible scaffolds, microcarriers, myoblast culture, serum-free media development and the bioprocess economics that decide whether cultivated protein ever becomes affordable. It has appeared in npj Science of Food, Acta Biomaterialia, Biofabrication, Small, Advanced Healthcare Materials, Organogenesis and Artificial Organs, and has been cited more than 1,190 times, giving him an h-index and i10-index of 11.

He is founder and chief executive of TechnoBiom, the cell-agriculture biotechnology platform he established in 2020 in Pasadena, California, developing edible scaffolds, microcarriers, hydrogel systems, AI-assisted media optimisation and low-cost alternatives to foetal bovine serum. In 2025 he co-founded OrgaBiom, an animal wellness venture developing species-specific probiotic and organ-targeted solutions.

He serves as biotechnology and biomedical investment advisor to the Royal Family of Dubai, United Arab Emirates, conducting scientific, operational and commercialisation due diligence across biomanufacturing, cultivated proteins, biomaterials, therapeutics, medical devices and applied artificial intelligence. He was previously Vice President of Innovation at Omeat and an affiliated scientist at the Terasaki Institute for Biomedical Innovation, and has served as chief editor of CultivatedMeats.org since 2022.

He is the author of three books on management and family enterprise, and co-founder of the Esmail Zamanian Addiction Medicine Award. He works in English and Farsi.

Interests: Dr. Zamanian is founder and chief executive of TechnoBiom and co-founder of OrgaBiom. Cell-Ag reports on the field in which those companies operate; any item touching them, or a direct competitor, carries that disclosure within the piece.